Cornell Alison A 4

What Happened

• Alison A. Cornell, a director of Zivo Bioscience, purchased 11,709 common shares in an open-market transaction on January 26, 2026. The shares were acquired at $8.54 each for a total cash outlay of $99,995. This was a direct purchase (Form 4 code P), which investors often view as a positive signal but is not a guarantee of future performance.

Key Details

• Transaction date: 2026-01-26
• Transaction type: Open-market purchase (Form 4 code P)
• Price and quantity: 11,709 shares at $8.54 per share; aggregate $99,995
• Shares owned after transaction: Not reported in the supplied filing data
• Filing date: 2026-01-28 (filed within typical 2-business-day window)
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other special footnotes were provided in the supplied details

Context

• This was a straightforward open-market purchase (not an option exercise, gift, or award). The filing does not indicate 10% owner status. For retail investors, director purchases can merit attention as a piece of information about insider activity, but should be considered alongside other company fundamentals and disclosures.